2025 H2 -tulosraportti
168 päivää sitten
‧38 min
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H1 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 | ||
2024 H1 -tulosraportti 30.8.2024 | ||
2023 H2 -tulosraportti 28.2.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
6 min sittenLes om Thor Medical sine patenter: What patents does Thor Medical hold to protect their method for producing high-purity isotopes to the radiopharmaceutical industry? Thor Medical ASA protects its irradiation‑free, high‑purity isotope production method primarily through patents held by its wholly owned subsidiary Sciencons AS (the company’s IP vehicle), covering the AlphaCycle™ separation/purification process and associated generators for producing Th‑228, Ra‑224, and Pb‑212 from natural thorium. Core patent family behind AlphaCycle™ Public filings and company materials point to a small but focused portfolio centered on gas‑emanation/separation generators and purification methods that avoid reactor/accelerator irradiation: U.S. Patent No. 12,249,437 – “Assemblies and method for obtaining a container comprising ²¹²Pb on the walls obtained from a ²¹²Pb precursor isotope source.” Filed 2024, granted 2025; assignee Sciencons AS. This covers systems/methods to generate highly purified ²¹²Pb using gaseous progeny (²²⁰Rn) separation from precursors such as ²²⁸Th/²²⁴Ra. U.S. Patent No. 11,306,038 – “Generation of lead‑212 for therapeutic use” (methods for ²¹²Pb‑labeled proteins/radioimmunoconjugates). Granted 2022; assignee Sciencons AS. While focused on downstream labeling, it is part of the same technical chain that starts with high‑purity ²¹²Pb generation. European Patent EP 3,474,904 B1 – “Preparation of ²¹²Pb labeled monoclonal antibodies.” Proprietor Sciencons AS; priority 2016. Again, this sits downstream but relies on the company’s ability to supply ultra‑pure ²¹²Pb. Older foundational generator patents (now expired) such as US 5,038,046 / EP 0,466,290 A1 describe the classic ²²⁸Th → ²²⁰Rn (gas) → ²¹²Pb emanation generator concept; Thor Medical/Sciencons’ current IP builds on and differentiates from this prior art with higher purity, scalability, and process controls suited to commercial GMP supply. Company disclosures consistently describe the protected know‑how as the AlphaCycle™ process: a proprietary, irradiation‑free separation and purification workflow that converts natural ²³²Th into high‑purity ²²⁸Th and, via decay and processing, into ²²⁴Ra and ²¹²Pb at industrial scale.
·7 min sittenI must admit that I am quite curious about today. Will we see further gains, or will there be a small correction? I have been surprised by the steady uptrend, and had thought it would fall yesterday. (Am a shareholder, been in for a long time, plans to sit long)
·12 t sitten
It is likely many have sold out completely, which makes the volume high and the gain over the last 2 days "minimal". We are probably rid of many now and are left with some long-term hands.
12 t sittenhttps://www.esmo.org/meeting-calendar/esmo-congress-2026 Will Advancell step into the spotlight at ESMO 2026? Time will tell... Rationale: - Clinically significant data (RP2D + long-term follow-up). - Unique isotope technology (Lead-212). - Massive funding and Big Pharma support. - Momentum in the TAT field at ESMO 2026.
When a client like AdvanCell (with Lilly backing them) gets to present clinical data at one of the world's largest cancer congresses, it's a strong signal that the Pb-212 platform is gaining more attention and credibility. The further AdvanCell progresses in clinical development, the greater the need for reliable access to Th-228.
·16 t sittenImpressive turnover today where 2% of the company has changed ownership. It is nevertheless strange to see that it is possible to buy in with such volumes and only move the price 4%. People are selling out too cheaply here.This is why "someone with a lot of capital" who is "running hard blocks" of "301000 shares" "for sale" at 6.40. That's how they keep doing it every day. They are buying with both hands at the same time. But wow, up 4 % today is good. Remember that without those hopeless blocks, it would have been up 22% today on such a large volume. Turnover increases every day. They like all of us who are long in Thor.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 H2 -tulosraportti
168 päivää sitten
‧38 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- 6 min sittenLes om Thor Medical sine patenter: What patents does Thor Medical hold to protect their method for producing high-purity isotopes to the radiopharmaceutical industry? Thor Medical ASA protects its irradiation‑free, high‑purity isotope production method primarily through patents held by its wholly owned subsidiary Sciencons AS (the company’s IP vehicle), covering the AlphaCycle™ separation/purification process and associated generators for producing Th‑228, Ra‑224, and Pb‑212 from natural thorium. Core patent family behind AlphaCycle™ Public filings and company materials point to a small but focused portfolio centered on gas‑emanation/separation generators and purification methods that avoid reactor/accelerator irradiation: U.S. Patent No. 12,249,437 – “Assemblies and method for obtaining a container comprising ²¹²Pb on the walls obtained from a ²¹²Pb precursor isotope source.” Filed 2024, granted 2025; assignee Sciencons AS. This covers systems/methods to generate highly purified ²¹²Pb using gaseous progeny (²²⁰Rn) separation from precursors such as ²²⁸Th/²²⁴Ra. U.S. Patent No. 11,306,038 – “Generation of lead‑212 for therapeutic use” (methods for ²¹²Pb‑labeled proteins/radioimmunoconjugates). Granted 2022; assignee Sciencons AS. While focused on downstream labeling, it is part of the same technical chain that starts with high‑purity ²¹²Pb generation. European Patent EP 3,474,904 B1 – “Preparation of ²¹²Pb labeled monoclonal antibodies.” Proprietor Sciencons AS; priority 2016. Again, this sits downstream but relies on the company’s ability to supply ultra‑pure ²¹²Pb. Older foundational generator patents (now expired) such as US 5,038,046 / EP 0,466,290 A1 describe the classic ²²⁸Th → ²²⁰Rn (gas) → ²¹²Pb emanation generator concept; Thor Medical/Sciencons’ current IP builds on and differentiates from this prior art with higher purity, scalability, and process controls suited to commercial GMP supply. Company disclosures consistently describe the protected know‑how as the AlphaCycle™ process: a proprietary, irradiation‑free separation and purification workflow that converts natural ²³²Th into high‑purity ²²⁸Th and, via decay and processing, into ²²⁴Ra and ²¹²Pb at industrial scale.
- ·7 min sittenI must admit that I am quite curious about today. Will we see further gains, or will there be a small correction? I have been surprised by the steady uptrend, and had thought it would fall yesterday. (Am a shareholder, been in for a long time, plans to sit long)
- ·12 t sittenIt is likely many have sold out completely, which makes the volume high and the gain over the last 2 days "minimal". We are probably rid of many now and are left with some long-term hands.
- 12 t sittenhttps://www.esmo.org/meeting-calendar/esmo-congress-2026 Will Advancell step into the spotlight at ESMO 2026? Time will tell... Rationale: - Clinically significant data (RP2D + long-term follow-up). - Unique isotope technology (Lead-212). - Massive funding and Big Pharma support. - Momentum in the TAT field at ESMO 2026.When a client like AdvanCell (with Lilly backing them) gets to present clinical data at one of the world's largest cancer congresses, it's a strong signal that the Pb-212 platform is gaining more attention and credibility. The further AdvanCell progresses in clinical development, the greater the need for reliable access to Th-228.
- ·16 t sittenImpressive turnover today where 2% of the company has changed ownership. It is nevertheless strange to see that it is possible to buy in with such volumes and only move the price 4%. People are selling out too cheaply here.This is why "someone with a lot of capital" who is "running hard blocks" of "301000 shares" "for sale" at 6.40. That's how they keep doing it every day. They are buying with both hands at the same time. But wow, up 4 % today is good. Remember that without those hopeless blocks, it would have been up 22% today on such a large volume. Turnover increases every day. They like all of us who are long in Thor.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H1 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 | ||
2024 H1 -tulosraportti 30.8.2024 | ||
2023 H2 -tulosraportti 28.2.2024 |
2025 H2 -tulosraportti
168 päivää sitten
‧38 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H1 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 | ||
2024 H1 -tulosraportti 30.8.2024 | ||
2023 H2 -tulosraportti 28.2.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- 6 min sittenLes om Thor Medical sine patenter: What patents does Thor Medical hold to protect their method for producing high-purity isotopes to the radiopharmaceutical industry? Thor Medical ASA protects its irradiation‑free, high‑purity isotope production method primarily through patents held by its wholly owned subsidiary Sciencons AS (the company’s IP vehicle), covering the AlphaCycle™ separation/purification process and associated generators for producing Th‑228, Ra‑224, and Pb‑212 from natural thorium. Core patent family behind AlphaCycle™ Public filings and company materials point to a small but focused portfolio centered on gas‑emanation/separation generators and purification methods that avoid reactor/accelerator irradiation: U.S. Patent No. 12,249,437 – “Assemblies and method for obtaining a container comprising ²¹²Pb on the walls obtained from a ²¹²Pb precursor isotope source.” Filed 2024, granted 2025; assignee Sciencons AS. This covers systems/methods to generate highly purified ²¹²Pb using gaseous progeny (²²⁰Rn) separation from precursors such as ²²⁸Th/²²⁴Ra. U.S. Patent No. 11,306,038 – “Generation of lead‑212 for therapeutic use” (methods for ²¹²Pb‑labeled proteins/radioimmunoconjugates). Granted 2022; assignee Sciencons AS. While focused on downstream labeling, it is part of the same technical chain that starts with high‑purity ²¹²Pb generation. European Patent EP 3,474,904 B1 – “Preparation of ²¹²Pb labeled monoclonal antibodies.” Proprietor Sciencons AS; priority 2016. Again, this sits downstream but relies on the company’s ability to supply ultra‑pure ²¹²Pb. Older foundational generator patents (now expired) such as US 5,038,046 / EP 0,466,290 A1 describe the classic ²²⁸Th → ²²⁰Rn (gas) → ²¹²Pb emanation generator concept; Thor Medical/Sciencons’ current IP builds on and differentiates from this prior art with higher purity, scalability, and process controls suited to commercial GMP supply. Company disclosures consistently describe the protected know‑how as the AlphaCycle™ process: a proprietary, irradiation‑free separation and purification workflow that converts natural ²³²Th into high‑purity ²²⁸Th and, via decay and processing, into ²²⁴Ra and ²¹²Pb at industrial scale.
- ·7 min sittenI must admit that I am quite curious about today. Will we see further gains, or will there be a small correction? I have been surprised by the steady uptrend, and had thought it would fall yesterday. (Am a shareholder, been in for a long time, plans to sit long)
- ·12 t sittenIt is likely many have sold out completely, which makes the volume high and the gain over the last 2 days "minimal". We are probably rid of many now and are left with some long-term hands.
- 12 t sittenhttps://www.esmo.org/meeting-calendar/esmo-congress-2026 Will Advancell step into the spotlight at ESMO 2026? Time will tell... Rationale: - Clinically significant data (RP2D + long-term follow-up). - Unique isotope technology (Lead-212). - Massive funding and Big Pharma support. - Momentum in the TAT field at ESMO 2026.When a client like AdvanCell (with Lilly backing them) gets to present clinical data at one of the world's largest cancer congresses, it's a strong signal that the Pb-212 platform is gaining more attention and credibility. The further AdvanCell progresses in clinical development, the greater the need for reliable access to Th-228.
- ·16 t sittenImpressive turnover today where 2% of the company has changed ownership. It is nevertheless strange to see that it is possible to buy in with such volumes and only move the price 4%. People are selling out too cheaply here.This is why "someone with a lot of capital" who is "running hard blocks" of "301000 shares" "for sale" at 6.40. That's how they keep doing it every day. They are buying with both hands at the same time. But wow, up 4 % today is good. Remember that without those hopeless blocks, it would have been up 22% today on such a large volume. Turnover increases every day. They like all of us who are long in Thor.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt